A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data

BACKGROUND: Castration-resistant prostate cancer (CRPC) represents one type of advanced prostate cancer (PCa) with a median survival time of 1–2 years. Currently, there is a lack of reliable gene panels in predicting hormone treatment (HT) responses due to limited knowledge of CRPC-specific tumor-mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Juanlan, Liu, Dale, Li, Jun, Xu, Jing, Dong, Shaowei, Zhang, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512812/
https://www.ncbi.nlm.nih.gov/pubmed/37729607
http://dx.doi.org/10.1080/07853890.2023.2260387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10512812/
https://www.ncbi.nlm.nih.gov/pubmed/37729607
http://dx.doi.org/10.1080/07853890.2023.2260387

Ejemplares similares